TABLE 2.
Methylated copies/mL of plasma and methylation status of SEPT9 and BMP3.
| Groups | N | cfDNA ng/mL median (min–max) | Copies/mL of plasma median (min–max) | Methylation status median (min–max) | |
|---|---|---|---|---|---|
| Methylated | Unmethylated | ||||
| SEPT9 | |||||
| Control/HP | 54 | 7 (1–29) | 4 (0–43) | 427 (34–1777) | 0% (0–3) |
| NAA | 113 | 8 (4–192) | 3 (0–170) | 412 (2–12,556) | 1% (0–12) |
| AA | 44 | 8 (4–50) | 4 (0–64) | 562 (37–2353) | 1% (0–4) |
| CRC | 36 | 10 (1–2268) | 16 (0–23,232) | 567 (15–107,490) | 2% (0–83) |
| I | 9 | 9 (1–106) | 5 (0–79) | 444 (208–5236) | 1% (0–5) |
| II | 8 | 10 (1–14) | 5 (0–271) | 391 (121–1191) | 2% (0–54) |
| III | 13 | 9 (1–71) | 16 (0–255) | 451 (69–1434) | 2% (0–30) |
| IV | 6 | 100 (4–2268) | 393 (136–23,232) | 523 (108–107,049) | 67% (20–83) |
| BMP3 | |||||
| Control/HP | 54 | 7 (1–29) | 0 (0–20) | 210 (48–1666) | 0% (0–11) |
| NAA | 110 | 8 (4–192) | 0 (0–42) | 300 (47–4992) | 0% (0–13) |
| AA | 45 | 8 (4–50) | 0 (0–10) | 234 (36–1131) | 0% (0–10) |
| CRC | 35 | 10 (1–2268) | 0 (0–725) | 239 (51–183,708) | 0% (0–84) |
| I | 9 | 9 (1–106) | 3 (0–57) | 444 (208–5236) | 4% (0–61) |
| II | 8 | 10 (1–14) | 0 (0–14) | 391 (121–1191) | 0% (0–63) |
| III | 12 | 9 (1–71) | 0 (0–81) | 417 (69–1434) | 0% (0–43) |
| IV | 6 | 100 (4–2268) | 20 (0–725) | 523 (108–107,049) | 6% (0–84) |
Abbreviations: AA, advanced adenoma; CRC, colorectal Cancer; HP, hyperplastic polyp; N, number of cases analyzed; NAA, nonadvanced adenoma; SSL, sessile serrated lesion.